Inadequate treatment with HMG-CoA reductase inhibitors by health care providers
References (17)
- et al.
Incidence of coronary heart disease and lipoprotein cholesterol levels.The Framingham study
JAMA
(1986) - et al.
Serum Cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial
Arch Intern Med
(1992) - et al.
Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms
NEJM
(1995) - et al.
Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management
Circulation
(1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Lancet
(1994)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
JAMA
(1993)HMG-CoA reductase inhibitors for treatment of hypercholesteremia
NEJM
(1988)Comparison of properties of four inhibitors of 3-Hydroxy-3-Methyglutaryl-Coenzyme A reductase
Am J Cardiol
(1994)
Cited by (176)
Active Lipid Management In Coronary Artery Disease (ALMICAD) Study
2007, American Journal of MedicineCitation Excerpt :Despite robust data about secondary prevention and national guidelines, hyperlipidemia is not adequately treated in clinical practice.9 The highest risk patients with established coronary artery disease, who benefit the most from lipid-lowering therapy, historically achieve LDL cholesterol targets at low rates in practice.10,11 Treatment of these patients in some specialized clinics has demonstrated better lipid control, but clinical efficacy studies are lacking.13,14
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: Comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR Trial
2007, Mayo Clinic ProceedingsCitation Excerpt :Use of more effective statins in the appropriate patient population could facilitate improved attainment of Health Plan Employer and Data Information Set performance goals by physicians and managed care organizations. Available data indicate that most patients continue treatment with initial statin doses in routine clinical practice and that LDL-C goals are achieved only infrequently in high-risk patients.1–4,7,22 Some reasons for inadequate titration in routine clinical practice may be the lack of resources at clinician offices to schedule more frequent visits, lack of adherence to or patient availability for recommended follow-up visits, and/or lack of standard programs, appropriately individualized, for patient management of dyslipidemia and atherosclerotic cardiovascular disease risk.23
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study
2007, AtherosclerosisCitation Excerpt :It is a widespread medical practice to initiate statin treatment at the lowest dose. Unfortunately, it is also common that doses are not titrated up in order to reach the recommended LDL-C goal [12–14]. Tailoring the starting dose according to individual LDL-C reduction requirements may aid in the achievement of target LDL-C levels [12,15].
Utilization of High-Intensity Statins in Patients at Risk for Cardiovascular Events: A National Cross-Sectional Study
2022, American Journal of Therapeutics